Emerging trends in viral infection inhibition using a chitosan-based drug delivery system

Viral diseases damage the host's cells and weaken the host's immunity, leading to multiple relapses or lasting a long time. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a prevalent infection that can cause immunostimulation, serious medical complications or even promote the risk of side effects and fatality, especially among older adults. Due to the replication process of the viral genome, it is significant to design and develop new pharmaceuticals to alleviate the illness and global death rates attributed to infection. Chitosan, a versatile biopolymer derived from natural sources, possesses cationic properties and has been employed to produce nanoparticles (NPs). These NPs exhibit biocompatibility, biodegradability, antimicrobial and anticancer properties, non-toxicity, ready availability, and the ability to function as drug delivery systems (DDSs). The physicochemical attributes of chitosan and its NPs in the transfer of bioactive agents are detected in nanotechnology, which can enhance anti-viral efficacy. This review highlights progressions in nanoscience for chitosan-based drug delivery in treating viral diseases. New research is expected to suggest new strategies in the field of DDS for the therapeutics of infectious diseases.